Stocks Health care HRTX
NASDAQ · Health careHeron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. brought in $151.2M of revenue over the twelve months to June 30, 2026, up 1.0% from a year earlier. It posted a net loss of $34M. In fiscal 2025 capital spending exceeded operating cash flow by $27.9M. At June 30, 2026 it held $20.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Heron Therapeutics, Inc. does
Heron Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $154.9M | -$20.2M | -$0.12 | -$27.9M |
| 2024 | $144.3M | -$13.6M | -$0.09 | -$24.2M |
| 2023 | $127M | -$110.6M | -$0.80 | -$60.3M |
| 2022 | $107.7M | -$182M | -$1.67 | -$148.7M |
| 2021 | $86.3M | -$220.7M | -$2.24 | -$206.4M |
| 2020 | $88.6M | -$227.3M | -$2.50 | -$191.6M |
Latest SEC filings
What Heron Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 10, 2026
- June 25, 2026
- June 16, 2026
- June 2, 2026Other event 8-K
- May 13, 2026Passive stake changed SCHEDULE 13G/A
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 30, 2026
Questions about HRTX
What does Heron Therapeutics, Inc. do?
Heron Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HRTX.
Is Heron Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34M on revenue of $151.2M.
How much revenue does Heron Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Heron Therapeutics, Inc. reported revenue of $151.2M. That is 1.0% more than a year earlier.
When did Heron Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from August 14, 2026.
Similar companies
Follow HRTX
Get an email when Heron Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow HRTX: get an email when it filesWhere the numbers come from
Financial figures are the values Heron Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.